drug_discovery

Nona Biosciences Debuts HCAbLM, First AI Model for Human HCAbs

Image
Nona Biosciences Debuts HCAbLM, First AI Model for Human HCAbs

Cambridge – September 19, 2026 -- Nona Biosciences has developed HCAbLM, the first language model trained specifically on fully human heavy-chain-only antibodies (HCAbs), built from a dataset of 31.8 million HCAb sequences drawn from 73 independently immunized transgenic mice. The findings were detailed in a study titled "A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies," published on bioRxiv.

Nona targets the developability bottleneck in AI antibody design

Current AI antibody discovery is limited less by target-binding design than by manufacturability at scale, aggregation risk and stability -- collectively known as developability. HCAbLM was built to learn the underlying sequence grammar that determines whether an HCAb can fold correctly and progress into a viable drug candidate. General-purpose protein models lack this capability because their training data contain almost no HCAb sequences.

EMD Serono Buys PostEra's AI-Designed Oral Fertility Drug Programs

Image
EMD Serono Buys PostEra's AI-Designed Oral Fertility Drug Programs

Boston – September 17, 2026 -- EMD Serono, Inc., the healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has acquired two preclinical fertility drug programs from PostEra, a biotech firm built on artificial intelligence-driven small molecule discovery.

PostEra's Proton platform generated oral agonists targeting two hard-to-drug fertility receptors

The acquired programs target the follicle-stimulating hormone receptor (FSHR) and the luteinizing hormone/choriogonadotropin receptor (LHCGR), both used over two years by PostEra's AI platform Proton to design small molecule candidates for reproductive endocrinology. FSHR agonists were developed for ovarian stimulation in in vitro fertilization (IVF), while LHCGR agonists target male infertility and ovulation triggering in IVF protocols.

Superluminal Medicines Closes $60M Series B for Obesity Drug

Image
Superluminal Medicines Closes $60M Series B for Obesity Drug

Boston – September 08, 2026 -- Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, L.P., to fund a Phase 1 clinical trial for rare genetic forms of obesity expected to begin by the end of 2026.

New investors Deep Track Capital and Perceptive Advisors join the round

The financing includes participation from new investors Deep Track Capital and Perceptive Advisors, alongside existing backers RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.